Structures by: Koztecki L. H.
Total: 6
3-(4-dibenzo[b,f][1,4]oxepin-11-yl-piperazin-1-yl)-2,2-dimethylpropanoic acid Hydrate A 1.95
C22H25N3O3,H3.90O1.95
Molecular pharmaceutics (2015) 12, 8 3069-3088
a=26.663(7)Å b=9.634(2)Å c=20.863(9)Å
α=90° β=128.322(6)° γ=90°
3-(4-dibenzo[b,f][1,4]oxepin-11-yl-piperazin-1-yl)-2,2-dimethylpropanoic acid Dihydrate
C22H25N3O3,2(H2O)
Molecular pharmaceutics (2015) 12, 8 3069-3088
a=13.212(2)Å b=9.1505(15)Å c=18.160(3)Å
α=90° β=105.195(11)° γ=90°
3-(4-dibenzo[b,f][1,4]oxepin-11-yl-piperazin-1-yl)-2,2-dimethylpropanoic acid Hydrate A 1.73
C22H25N3O3,H3.46O1.73
Molecular pharmaceutics (2015) 12, 8 3069-3088
a=26.498(3)Å b=9.6469(8)Å c=20.342(3)Å
α=90° β=128.706(4)° γ=90°
3-(4-(benzo[d]isoxazole-3-yl)piperazin-1-yl)-2,2-dimethylpropanoic acid
C16H21N3O3
Crystal Growth & Design (2014) 14, 4 2056
a=14.0905(3)Å b=6.25060(10)Å c=17.0170(3)Å
α=90° β=91.3210(10)° γ=90°
3-(4-dibenzo[b,f][1,4]oxepin-11-yl-piperazin-1-yl)-2,2-dimethylpropanoic acid
C22H25N3O3
Crystal Growth & Design (2014) 14, 4 2056
a=9.3970(3)Å b=10.8925(3)Å c=11.0095(4)Å
α=65.728(2)° β=67.321(2)° γ=77.584(2)°
3-(4-dibenzo[b,f][1,4]oxepin-11-yl-piperazin-1-yl)-2,2-dimethylpropanoic acid
C22H25N3O3
Crystal Growth & Design (2014) 14, 4 2056
a=9.2754(4)Å b=10.0504(5)Å c=11.8580(6)Å
α=106.010(4)° β=108.236(3)° γ=99.895(3)°